User Tools

Site Tools


ohdsi-questions

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
ohdsi-questions [2018/04/15 12:38]
rohit
ohdsi-questions [2018/06/04 20:14] (current)
nigam
Line 1: Line 1:
-====OHDSI-Questions====+==== OHDSI-Questions ==== 
 + 
 +=== Question - 1 ===
  
-===Question - 1===  
 To compare the risk of post-hospital discharge mortality between patients with an exposure to assisted thoracoscopic surgery versus open resection. To compare the risk of post-hospital discharge mortality between patients with an exposure to assisted thoracoscopic surgery versus open resection.
-  -Treatment Cohort - Patients with known or suspected lung cancer on assisted thoracoscopic surgery. 
-  -Comparator Cohort - Patients with known or suspected lung cancer on open resection. 
-  -Outcome - Mortality after 30, 60 and 90 days after discharge from the hospital. ​   
-  -Risk Window - 30, 60 and 90 days after discharge from hospital up to 3 years. 
  
-===Question - 2===+  - Treatment Cohort - Patients with known or suspected lung cancer on assisted thoracoscopic surgery. 
 +  - Comparator Cohort - Patients with known or suspected lung cancer on open resection. 
 +  - Outcome - Mortality after 30, 60 and 90 days after discharge from the hospital. 
 +  - Risk Window - 30, 60 and 90 days after discharge from hospital up to 3 years. 
 + 
 +=== Question - 2 === 
 To compare the risk of developing opioid addiction in patients with an opioid prescription. To compare the risk of developing opioid addiction in patients with an opioid prescription.
-  -Treatment Cohort - Patients prescribed an opioid (hydrocodone,​ oxycodone, morphine, and codeine) who developed addiction in the following one year. 
-  -Comparator Cohort - Patients prescribed an opioid (hydrocodone,​ oxycodone, morphine, and codeine) who did not develop an opioid addiction. ​ 
-  -Outcome - Development of opioid addiction. 
-  -Risk Window - One year from the time of first opioid prescription. 
  
-===Question - 3===+  - Treatment Cohort - Patients prescribed an opioid (hydrocodone,​ oxycodone, morphine, and codeine) who developed addiction in the following one year. 
 +  - Comparator Cohort - Patients prescribed an opioid (hydrocodone,​ oxycodone, morphine, and codeine) who did not develop an opioid addiction. 
 +  - Outcome - Development of opioid addiction. 
 +  - Risk Window - One year from the time of first opioid prescription. 
 + 
 +=== Question - 3 === 
 To compare the risk of amputation between diabetic patients treated with canagliflozin versus diabetic patients treated with other diabetic drugs. To compare the risk of amputation between diabetic patients treated with canagliflozin versus diabetic patients treated with other diabetic drugs.
-  -Treatment Cohort - Diabetic patients treated with canagliflozin. 
-  -Comparator Cohort - Diabetic patients treated with other diabetic drugs or other forms of SGLT-2 inhibitors. ​ 
-  -Outcome - Amputation after treatment. 
-  -Risk Window - 1 day after treatment exposure or 0 days after exposure end to end of the patient timeline.  ​ 
  
-===Question - 4===+  - Treatment Cohort - Diabetic patients treated with canagliflozin. 
 +  - Comparator Cohort - Diabetic patients treated with other diabetic drugs or other forms of SGLT-2 inhibitors. 
 +  - Outcome - Amputation after treatment. 
 +  - Risk Window - 1 day after treatment exposure or 0 days after exposure end to end of the patient timeline. 
 + 
 +=== Question - 4 === 
 To compare the risk of mortality between patients with bladder cancer treated with aspirin for one year versus patients with bladder cancer not treated with aspirin. To compare the risk of mortality between patients with bladder cancer treated with aspirin for one year versus patients with bladder cancer not treated with aspirin.
-  -Treatment Cohort - Patients with bladder cancer treated with aspirin at least for one year. 
-  -Comparator Cohort - Patients with bladder cancer not treated with aspirin. 
-  -Outcome - Mortality after treatment. 
-  -Risk Window -  1 day after treatment exposure up to 5 years after treatment exposure end. 
  
-===Question - 5===+  - Treatment Cohort - Patients with bladder cancer treated with aspirin at least for one year. 
 +  - Comparator Cohort - Patients with bladder cancer not treated with aspirin. 
 +  - Outcome - Mortality after treatment. 
 +  - Risk Window - 1 day after treatment exposure up to 5 years after treatment exposure end. 
 + 
 +=== Question - 5 === 
 To compare the risk of mortality between patients with heart disease treated with clarithromycin versus patients with heart disease treated with amoxicillin. To compare the risk of mortality between patients with heart disease treated with clarithromycin versus patients with heart disease treated with amoxicillin.
-  -Treatment Cohort - Patients with heart disease treated with clarithromycin. 
-  -Comparator Cohort - Patients with heart disease treated with amoxicillin. 
-  -Outcome - Mortality. 
-  -Risk Window - 6 Years after treatment exposure. ​ 
  
-===Question - 6===+  - Treatment Cohort - Patients with heart disease treated with clarithromycin. 
 +  - Comparator Cohort - Patients with heart disease treated with amoxicillin. 
 +  - Outcome - Mortality. 
 +  - Risk Window - 6 Years after treatment exposure. 
 + 
 +=== Question - 6 === 
 To compare the risk of opportunistic infections between patients with anaplastic large cell lymphoma (ALCL) or Hodgkin lymphoma (HL) treated with CD30 inhibitors versus patients with ALCL or HL treated with antineoplastics or immunomodulators. To compare the risk of opportunistic infections between patients with anaplastic large cell lymphoma (ALCL) or Hodgkin lymphoma (HL) treated with CD30 inhibitors versus patients with ALCL or HL treated with antineoplastics or immunomodulators.
-  -Treatment Cohort - Patient with ALCL or HL treated with brentuximab. 
-  -Comparator Cohort - Patients with ALCL or HL treated with either antineoplastics or immunomodulators or both. 
-  -Outcome - Diagnosis of opportunistic infections. 
-  -Risk Window - 1 day after treatment exposure starts to 90 days after treatment exposure end.  
  
-===Question - 7===+  - Treatment Cohort - Patient with ALCL or HL treated with brentuximab. 
 +  - Comparator Cohort - Patients with ALCL or HL treated with either antineoplastics or immunomodulators or both. 
 +  - Outcome - Diagnosis of opportunistic infections. 
 +  - Risk Window - 1 day after treatment exposure starts to 90 days after treatment exposure end. 
 + 
 +=== Question - 7 === 
 To compare the risk of mortality between patients with asthma treated with inhaled long-acting muscarinic antagonists (LAMA) without concomitant use of inhaled corticosteroids (IC) versus patients with asthma treated with LAMA and IC. To compare the risk of mortality between patients with asthma treated with inhaled long-acting muscarinic antagonists (LAMA) without concomitant use of inhaled corticosteroids (IC) versus patients with asthma treated with LAMA and IC.
-  -Treatment Cohort - Patients with asthma treated with LAMA or LAMA and long-acting beta2-agonists (LABA) or leukotriene receptor antagonists (LTRA). 
-  -Comparator Cohort - Patients with asthma treated with LAMA and IC as a combination of either LAMA and IC only or LAMA and IC and LABA or LTRA.  
-  -Outcome - All-cause mortality as the primary outcome and asthma-related mortality as a secondary outcome. 
-  -Risk Window - 1st day of treatment exposure to end of the study. ​ 
  
 +  - Treatment Cohort - Patients with asthma treated with LAMA or LAMA and long-acting beta2-agonists (LABA) or leukotriene receptor antagonists (LTRA).
 +  - Comparator Cohort - Patients with asthma treated with LAMA and IC as a combination of either LAMA and IC only or LAMA and IC and LABA or LTRA.
 +  - Outcome - All-cause mortality as the primary outcome and asthma-related mortality as a secondary outcome.
 +  - Risk Window - 1st day of treatment exposure to end of the study.
  
-===Question - 8=== +=== Question - 8 ===
-(Not sure what C/D stand for, I’ve asked this on the forum and will update once get a reply). +
-To compare the risk of asthma exacerbations between patients with Chronic Obstructive Pulmonary Disease (COPD) C/D and inhaled corticosteroids withdrawal versus patients with COPD C/D who have never used ICS. +
-  -Treatment Cohort - Patients with COPD and inhaled corticosteroids withdrawal. +
-  -Comparator Cohort - Patients with COPS not exposed to inhaled corticosteroids.  +
-  -Outcome - Asthma Exacerbations. +
-  -Risk Window - 1 day after last exposure start to 180 days after the exposure end.+
  
 +(Not sure what C/D stand for, I’ve asked this on the forum and will update once get a reply). To compare the risk of asthma exacerbations between patients with Chronic Obstructive Pulmonary Disease (COPD) C/D and inhaled corticosteroids withdrawal versus patients with COPD C/D who have never used ICS.
 +
 +  - Treatment Cohort - Patients with COPD and inhaled corticosteroids withdrawal.
 +  - Comparator Cohort - Patients with COPS not exposed to inhaled corticosteroids.
 +  - Outcome - Asthma Exacerbations.
 +  - Risk Window - 1 day after last exposure start to 180 days after the exposure end.
 +
 +=== Question - 9 ===
  
-===Question - 9=== 
 To compare the risk of serious cardiovascular events (sudden cardiac death, acute myocardial infarction, and stroke) between the new users of triptans versus patients who used triptans for one year (short-term) and more than one year (long-term). To compare the risk of serious cardiovascular events (sudden cardiac death, acute myocardial infarction, and stroke) between the new users of triptans versus patients who used triptans for one year (short-term) and more than one year (long-term).
-  -Treatment Cohort - New users treated with triptans. 
-  -Comparator Cohort - Patients treated with triptans for one year (short-term) and patients treated with triptans for more than one year (long-term). 
-  -Outcome - Sudden cardiac death, acute myocardial infarction, and stroke after exposure. 
-  -Risk Window - 1 day after treatment exposure starts to 0 days after treatment exposure ends.  
  
-===Question - 10===+  - Treatment Cohort - New users treated with triptans. 
 +  - Comparator Cohort - Patients treated with triptans for one year (short-term) and patients treated with triptans for more than one year (long-term). 
 +  - Outcome - Sudden cardiac death, acute myocardial infarction, and stroke after exposure. 
 +  - Risk Window - 1 day after treatment exposure starts to 0 days after treatment exposure ends. 
 + 
 +=== Question - 10 === 
 To compare the risk of osteoporosis or fracture increase in postmenopausal hypothyroid patients using high strength levothyroxine versus patients using low strength levothyroxine. To compare the risk of osteoporosis or fracture increase in postmenopausal hypothyroid patients using high strength levothyroxine versus patients using low strength levothyroxine.
-  -Treatment Cohort - On treatment postmenopausal (age >=50 years) patients with hypothyroidism exposed to high strength of levothyroxine (>=0.044 mg/​day). ​ 
-  -Comparator Cohort - On treatment postmenopausal (age >=50 years) patients with hypothyroidism exposed to low strength of levothyroxine (< 0.044 mg/day). 
-  -Outcome - Osteoporosis or Fracture. 
-  -Risk Window: From the first day of treatment with high or low strength levothyroxine until the end of cohort study, end of follow-up or death. 
  
-===Question - 11===+  - Treatment Cohort - On treatment postmenopausal (age >=50 years) patients with hypothyroidism exposed to high strength of levothyroxine (>=0.044 mg/day). 
 +  - Comparator Cohort - On treatment postmenopausal (age >=50 years) patients with hypothyroidism exposed to low strength of levothyroxine (< 0.044 mg/day). 
 +  - Outcome - Osteoporosis or Fracture. 
 +  - Risk Window: From the first day of treatment with high or low strength levothyroxine until the end of cohort study, end of follow-up or death. 
 + 
 +=== Question - 11 === 
 To compare the risk of chronic kidney disease (CKD) among patients exposed to proton pump inhibitors versus patients not exposed to proton pump inhibitors. To compare the risk of chronic kidney disease (CKD) among patients exposed to proton pump inhibitors versus patients not exposed to proton pump inhibitors.
-  -Treatment Cohort - Patients with chronic exposure to proton pump inhibitors, age >= 18 years heaving no evidence of chronic kidney disease (eGFR < 60ml/min). 
-  -Comparator Cohort - Patients of age >= 18 with no exposure to proton pump inhibitors. 
-  -Outcome - Incidence of chronic kidney disease. ​ 
  
-===Question - 12=== +  ​- Treatment Cohort - Patients with chronic exposure to proton pump inhibitors, age >= 18 years heaving no evidence ​of chronic kidney disease (eGFR < 60ml/min)
-To compare the risk of Atherosclerotic Cardiovascular Disease (ACD) between patients with a diagnosis of hyperlipidemia (HLD) on statins and elevated triglycerides treated with fibrates versus patients with a diagnosis of HLD on statins and elevated triglycerides not treated with fibrates.  +  - Comparator ​Cohort ​- Patients of age >= 18 with no exposure to proton pump inhibitors
-  ​-Treatment Cohort - Patients with a diagnosis ​of HLD on statins and elevated triglycerides treated with fibrates+  - Outcome - Incidence ​of chronic kidney ​disease.
-  -Comparator ​cohort ​- Patients ​with a diagnosis ​of HLD on statins and elevated triglycerides not treated ​with fibrates  +
-  -Outcome - Occurrence ​of Atherosclerotic Cardiovascular ​disease ​after treatment.  +
-  -Risk Window - 1 day after exposure start to 0 days after exposure ends.+
  
-===Question - 13=== +=== Question - 12 === 
-To compare the risk of Atherosclerotic Cardiovascular Disease (ACD) between patients with a diagnosis of hyperlipidemia (HLD) on statins with ideal cholesterol versus patients with a diagnosis of HLD on statins with elevated cholesterol.  + 
-  -Treatment Cohort - Patients with the diagnosis of HLD treated with statins and have ideal cholesterol level. +To compare the risk of Atherosclerotic Cardiovascular Disease (ACD) between patients with a diagnosis of hyperlipidemia (HLD) on statins and elevated triglycerides treated with fibrates versus patients with a diagnosis of HLD on statins and elevated triglycerides not treated with fibrates. 
-  -Comparator Cohort - Patients with the diagnosis of HLD treated with statins and have elevated cholesterol level.  + 
-  -Outcome - Risk of ACD. +  - Treatment Cohort - Patients with a diagnosis of HLD on statins and elevated triglycerides treated with fibrates. 
-  -Risk Window - 30 days after exposure to statins to 0 days after exposure. ​+  - Comparator cohort - Patients with a diagnosis of HLD on statins and elevated triglycerides not treated with fibrates. 
 +  - Outcome - Occurrence of Atherosclerotic Cardiovascular disease after treatment. 
 +  - Risk Window - 1 day after exposure start to 0 days after exposure ends. 
 + 
 +=== Question - 13 === 
 + 
 +To compare the risk of Atherosclerotic Cardiovascular Disease (ACD) between patients with a diagnosis of hyperlipidemia (HLD) on statins with ideal cholesterol versus patients with a diagnosis of HLD on statins with elevated cholesterol. 
 + 
 +  - Treatment Cohort - Patients with the diagnosis of HLD treated with statins and have ideal cholesterol level. 
 +  - Comparator Cohort - Patients with the diagnosis of HLD treated with statins and have elevated cholesterol level. 
 +  - Outcome - Risk of ACD. 
 +  - Risk Window - 30 days after exposure to statins to 0 days after exposure. 
 + 
 +=== Question - 14 ===
  
-===Question - 14=== 
 To compare the risk of developing malignancy in patients with moderate to severe rheumatoid arthritis treated with tofacitinib and tumor necrosis factor inhibitors (TNFi). To compare the risk of developing malignancy in patients with moderate to severe rheumatoid arthritis treated with tofacitinib and tumor necrosis factor inhibitors (TNFi).
-  -Treatment Cohort - Patients with moderate to severe rheumatoid arthritis treated with tofacitinib. 
-  -Comparator Cohort - Patients with moderate to severe rheumatoid arthritis treated with TNFi. 
-  -Outcome - Any type of malignancy. ​ 
  
- +  - Treatment Cohort - Patients with moderate to severe rheumatoid arthritis treated with tofacitinib. 
 +  - Comparator Cohort - Patients with moderate to severe rheumatoid arthritis treated with TNFi. 
 +  - Outcome - Any type of malignancy.
  
 More discussion on these question can be seen here at [[http://​forums.ohdsi.org/​t/​ohdsi-face-to-face-at-columbia-may2-3-community-study-a-thon/​4008/​10|OHDSI Forum]] More discussion on these question can be seen here at [[http://​forums.ohdsi.org/​t/​ohdsi-face-to-face-at-columbia-may2-3-community-study-a-thon/​4008/​10|OHDSI Forum]]
 +
 +
ohdsi-questions.txt · Last modified: 2018/06/04 20:14 by nigam